Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Antibody Files to List ADRs on the Nasdaq

NEW YORK, April 4 – Cambridge Antibody Technology of Melbourn, UK, said Wednesday it had filed a request with the US Securities and Exchange Commission to list American Depositary Receipts on the Nasdaq.

Rowena Gardner, head of corporate communications at CAT, said the company, which trades on the London Stock Exchange, decided to list ADRs on the Nasdaq in order to better service investors.

“Forty percent of our investors are in the states,” Gardner said.

She said she did not know when the ADRs would be listed, but added that she believed the company was towards the end of the regulatory process.

CAT uses develops human monoclonal antibodies for drug discovery and development and is also in agreements to develop protein chips through collaborations with Zyomyx and Oxford Glycosciences.

The company raised 41 million pounds ($58.8 million) in its March 1997 initial public offering and 93 million pounds in a secondary offering in March last year.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.